Connect with us

Politics

House Rejects AOC Amendment To Make It Easier To Study Psychedelic Drugs

Published

on

The House of Representatives rejected an amendment on Thursday that would have removed an existing rider that scientists say inhibits research into the therapeutic potential of Schedule I controlled substances such as psilocybin, MDMA and marijuana.

The amendment, introduced by Rep. Alexandria Ocasio-Cortez (D-NY) last week, would have eliminated a section of a large-scale appropriations bill stipulating that no federal dollars can be spent on “any activity that promotes the legalization of any drug or other substance in Schedule I.”

The presiding officer ruled that the measure was approved in a voice vote after the debate early Thursday morning, but that was reversed during a later roll call vote of 91 to 331.

“Academics and scientists report that provisions like this create [stigma] and insurmountable logistical hurdles to researching schedule I drugs like psilocybin and MDMA which have shown promise in end of life therapy and treating PTSD,” a summary of the amendment states.

The House Rules Committee cleared the proposal for floor consideration before the full chamber on Monday. However, during the same meeting it blocked a separate amendment that would have barred the Department of Education from denying or limiting funds to universities that allow the use or possession of medical cannabis on campus in a legal state.

Ocasio-Cortez’s measure was cosponsored by Reps. Lou Correa (D-NY), Ro Khanna (D-CA) and Matt Gaetz (R-FL).

“I’m a strong believer in evidence-based policymaking,” Ocasio-Cortez said during the floor debate. “And wherever there is evidence of good, we have a moral obligation to pursue and explore the parameters of that good. Even if it means challenging our past assumptions or admitting past wrongs.”

Describing the current situation researchers face as a “catch-22,” she said that the problem with the current policy is that it is “so vague and broadly interrupted that it prevents scientists from researching, examining and exploring avenues of treatment that could alleviate an enormous amount of suffering from medical conditions.”

Correa also spoke in support.

“We need legitimate, reliable research by universities and other institutions into the health benefits of cannabis and other substances,” he said. “This amendment will allow credible research institutions to conduct research by removing layers of paperwork that serve as hurdles meant to block such research. As more Americans, including veterans, use cannabis and so-called ‘magic mushrooms’ to manage or treat their pain or other health conditions, it’s important that doctors have the necessary information on the possible benefits, or not, of these substances.”

Correa called the amendment “both timely and very necessary” in light of recent local moves to reform criminal policies dealing with psychedelics.

Voters in Denver approved a local measure to decriminalize the substance last month, and the Oakland City Council unanimously passed a similar measure last week that also applies to other psychedelics including ayahuasca, mescaline and ibogaine.

Both Correa and Ocasio-Cortez spoke about the suicide rate among military veterans and the potential of psychedelics to help them with conditions such as post-traumatic stress disorder.

“Thirty percent of all military veterans have considered suicide. If a substance shows promise in treating PTSD, we have an obligation to study it,” Ocasio-Cortez said. “One of the leading causes of death in America today is suicide. So if a Schedule I drug shows clinical promise in treating and in treatment resistant depression, perhaps it is not the drug we should say morally wrong, but perhaps it is the law, the schedule, the statute.”

But Rep. Andy Harris (R-MD) rose to oppose the amendment, saying that it wouldn’t actually help to foster research, a goal he said he shares.

“The bottom line is, this is not the place and this won’t do what the authors in support of the amendment say it’s going to do. The fact of the matter is that the DEA is the one that enforces the classification of Schedule I. This bill does nothing to do with the DEA,” he argued. “The problem lies in the fact that it is a Schedule I drug and the appropriate way to deal with this is through an authorizing committee.”

A longtime opponent of legalization, Harris suggested that cannabis “induces psychosis in young people,” adding that it is “a gateway drug.”

The amendment, he said, “sends a bad signal” and isn’t just about marijuana. “It’s about every Schedule I drug. And there are very dangerous schedule 1 drugs.”

Rep. Scott Perry (R-PA) also spoke against the proposal.

“Do we want the federal government telling our families and our children, take this, it’s good for you?” he asked. “Maybe it is. I sure don’t think it is. I certainly don’t want my kids taking it and I don’t want the government promoting it.”

Citing the growing political support for marijuana reform at a time when tobacco use rates are at historic lows, Perry said, “now we’re going to tell the rest of the country, ‘let’s all start smoking marijuana instead.”

“I don’t think this is what the government should be promoting,” he said.

But Ocasio-Cortez argued that her amendment has bipartisan appeal.

“My colleagues on the other side of the aisle often bemoan the role of government and promote ideas of choice. And here I am happy in that spirit to agree,” she said. “We should get government and political opinion out of scientific research when we have seen and shown promise in a way that can help people and their medical needs.”

“I understand that the politics of this bill may make it difficult for some to support right now,” she said. “But I propose this amendment and urge my colleagues to support it because politics isn’t always about winning today, but it is about fighting for what is right in the future and for future generations.”

If Ocasio-Cortez’s amendment had passed through the House, and deleted from that chamber’s bill the longstanding prohibition on advocating legalization that was first enacted in 1996, that wouldn’t have necessarily meant that the rider would have ultimately been removed from federal law. The Senate Appropriations Committee has not yet introduced its version of the funding legislation.

The last few weeks has seen a significant uptick in cannabis reform being pursued through the congressional appropriations process, with multiple committee reports urging the adoption on marijuana legislation. Committees have called for provisions on regulating CBD, implementing hemp policies, lifting barriers to cannabis research, preventing impaired driving, protecting veteran benefits and requesting that the federal government reconsider its employment policies as it relates to federal workers who use cannabis in compliance with state laws.

On Tuesday, the House Appropriations Committee approved a spending bill that includes a section providing protections for banks that service state-legal marijuana business and also remove a longstanding rider that has blocked Washington, D.C. from using its own local tax dollars to legalize and regulate cannabis sales.

Anti-Marijuana Lawmakers Shut Down By Congressional Committee

Update: This story has been updated to include information about the roll call vote on the amendment.

Photo courtesy of Rick Proctor.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Sacramento-based senior editor. His work has also appeared in High Times, VICE and attn.

Politics

Congressman Files New Marijuana Banking Reform Amendment To Large-Scale House Bill

Published

on

The House sponsor of a bill to protect banks that work with state-legal marijuana businesses announced on Friday that he is seeking to attach an amendment containing the reform to a broader bill dealing with research and innovation in the tech and manufacturing sectors.

Rep. Ed Perlmutter (D-CO), sponsor of the Secure and Fair Enforcement (SAFE) Banking Act, has expressed interest in finding another vehicle to pursue his proposal after it was stripped from a separate defense bill late last year. The congressman’s legislation has cleared the House in five forms at this point, only to stall in the Senate.

His latest attempt to get the reform enacted is by filing an amendment with the SAFE Banking language to the America COMPETES Act, which does not deal specifically with cannabis issues as drafted but was introduced in the House this week.

“Cannabis-related businesses—big and small—and their employees are in desperate need of access to the banking system and access to capital in order to operate in an efficient, safe manner and compete in the growing global cannabis marketplace,” Perlmutter, who is retiring from Congress after this session and committed to passing his bill first, said in a press release.

“The SAFE Banking Act is the best opportunity to enact some type of federal cannabis reform this year and will serve as the first of many steps to help ensure cannabis businesses are treated the same as any other legal, legitimate business,” he said. “I will continue to pursue every possible avenue to get SAFE Banking over the finish line and signed into law.”

It remains to be seen whether the America COMPETES Act will serve as a more effective vehicle for the cannabis banking bill than the National Defense Authorization Act (NDAA), where the language was successfully attached on the House side but later removed amid bicameral negotiations. Perlmutter said at the time that Senate leadership, which is working on comprehensive legalization legislation, was to blame for the decision to remove his amendment from the proposal.

The new SAFE Banking Act amendment will still need to be made in order by the House Rules Committee in order to be formally be considered on the House floor when the body takes up the research and innovation package. The deadline to file amendments was Friday, and the panel is set to take them up starting on Tuesday.

Even some Republicans are scratching their heads about how Democrats have so far failed to pass the modest banking reform with majorities in both chambers and control of the White House. For example, Rep. Rand Paul (R-KY) criticized his Democratic colleagues over the issue last month.

In the interim, federal financial regulator Rodney Hood—a board member and former chairman of the federal National Credit Union Administration (NCUA)—recently said that marijuana legalization is not a question of “if” but “when,” and he’s again offering advice on how to navigate the federal-state conflict that has left many banks reluctant to work with cannabis businesses.

Ohio Lawmakers Will Be Forced To Consider Marijuana Legalization As State Validates Activist Signatures

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Ohio Lawmakers Will Be Forced To Consider Marijuana Legalization As State Validates Activist Signatures

Published

on

Ohio activists have collected enough signatures to force the legislature to take up the issue of marijuana legalization, the secretary of state’s office confirmed on Friday.

This comes about two weeks after the Coalition to Regulate Marijuana Like Alcohol (CTRMLA) submitted a final round of signatures for the measure. The petitions’ formal validation triggers the legislative review of legalization, but it does not require lawmakers to enact the reform.

The legislature now has four months to consider the campaign’s cannabis reform proposal. Lawmakers can adopt the measure, reject it or pass an amended version. If they do not pass the measure, organizers can then collect an additional 132,887 valid signatures from registered voters to place the issue on the ballot in November.

CTRMLA previously submitted petitions for the initiative but the state said they were short some 13,000 signatures, requiring activists to go back and make up the difference.

“We are ready and eager to work with Ohio legislators over the next four months to legalize the adult use of marijuana in Ohio,” CTRMLA spokesman Tom Haren said in a press release. “We are also fully prepared to collect additional signatures and take this issue directly to voters on November 8, 2022, if legislators fail to act.”

The measure that lawmakers will be required to consider would legalize possession of up to 2.5 ounces of cannabis for adults 21 and older, and they could also have up to 15 grams of marijuana concentrates. Individuals could grow up to six plants for personal use, with a maximum 12 plants per household.

A 10 percent sales tax would be imposed on cannabis sales, with revenue being divided up to support social equity and jobs programs (36 percent), localities that allow adult-use marijuana enterprises to operate in their area (36 percent), education and substance misuse programs (25 percent) and administrative costs of implementing the system (three percent).

A Division of Cannabis Control would be established under the state Department of Commerce. It would have authority to “license, regulate, investigate, and penalize adult use cannabis operators, adult use testing laboratories, and individuals required to be licensed.”

The measure gives current medical cannabis businesses a head start in the recreational market. Regulators would need to begin issuing adult-use licenses to qualified applicants who operate existing medical operations within nine months of enactment.

The division would also be required to issue 40 recreational cultivator licenses and 50 adult-use retailer licenses “with a preference to applications who are participants under the cannabis social equity and jobs program.” And it would authorize regulators to issue additional licenses for the recreational market two years after the first operator is approved.

Individual municipalities would be able to opt out of allowing new recreational cannabis companies from opening in their area, but they could not block existing medical marijuana firms even if they want to add co-located adult-use operations. Employers could also maintain policies prohibiting workers from consuming cannabis for adult use.

Further, regulators would be required to “enter into an agreement with the Department of Mental Health and Addiction Services” to provide “cannabis addiction services,” which would involve “education and treatment for individuals with addiction issues related to cannabis or other controlled substances including opioids.”

With respect to social equity, some advocate are concerned about the lack of specific language on automatic expungements to clear the records of people with convictions for offenses that would be made legal under the legislation. That said, it does include a provision requiring regulators to “study and fund” criminal justice reform initiatives including expungements.

Ohio voters rejected a 2015 legalization initiative that faced criticism from many reform advocates because of an oligopolistic model that would’ve granted exclusive control over cannabis production to the very funders who paid to put the measure on the ballot.

Activists suspended a campaign to place another measure on the 2020 ballot due to the coronavirus pandemic.

Aside from the new voter initiative, state lawmakers from both parties are separately working to advance marijuana reform.

A legalization bill that was the first of its kind to be introduced in the Ohio legislature last year would legalize the possession, sale and cultivation of cannabis by adults. It’s being championed by Reps. Casey Weinstein (D) and Terrence Upchurch (D).

A pair of Ohio Republican lawmakers similarly filed a bill to legalize marijuana in the state in December. Reps. Jamie Callender (R) and Ron Ferguson (R) first announced their plan to push the legislative reform proposal in October and circulated a co-sponsorship memo to build support for the measure.

There are also additional local reform efforts underway in Ohio for 2022.

After voters in seven cities approved ballot measures to decriminalize marijuana possession during last November’s election—which builds on a slew of previous local reforms in the state—campaigns are now looking to enact decriminalization in Marietta, Rushville, Rutland, Shawnee, McArthur and Laurelville.

Ohio marijuana activists already successfully proved that they turned in enough valid signatures to put a local decriminalization initiative before Kent voters after having missed the 2021 ballot due to a verification error on the part of county officials. That measure is now expected to go before voters this November.

Top Federal Drug Official Says Marijuana Use ‘Stable’ Among Youth At Prohibitionist-Hosted Panel Sponsored By D.A.R.E.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Top Federal Drug Official Says Marijuana Use ‘Stable’ Among Youth At Prohibitionist-Hosted Panel Sponsored By D.A.R.E.

Published

on

A top federal drug official participated in a panel hosted by a prohibitionist group and sponsored by D.A.R.E.—and she again reiterated that data shows youth marijuana use has remained stable “despite the legalization in many states.”

While National Institute on Drug Abuse (NIDA) Director Nora Volkow expressed concerns about certain cannabis trends related to potency, commercialization and use by pregnant women, she affirmed that surveys funded by her own federal agency have demonstrated that adolescent marijuana use is “stable,” despite repeated arguments from prohibitionists that legalization would lead more young people to experiment with cannabis.

The event was hosted by Smart Approaches to Marijuana (SAM), an anti-legalization group. SAM President Kevin Sabet and the organization’s co-founder former Rep. Patrick Kennedy (D-RI) led the discussion.

Sabet said that data on youth use has showed varying results in states that have legalized cannabis and asked Volkow to weigh in on the issue. She replied that federal data “have not been able to see large differences in terms of prevalence” of cannabis consumption among young people in legal and non-legal states.

The official made similar comments in an interview with Marijuana Moment late last year.

That said, Volkow said that they have seen some differences when it comes to consumption rates among adolescents for edible cannabis products.

“But the effects are not large, and one of the things that also certainly surprised me [is] the rate overall, the prevalence rates of marijuana use among teenagers, have been stable despite the legalization in many states,” she said, adding that there are some concerns about increased frequency of use and limitations in data collection with respect to dosages being taken.

Volkow also commented on a recent federally funded survey that found illicit drug use by young people has taken a significant plunge in the last year, though she largely attributed that to the reduced social interaction resulting from COVID-19 policies across the country.

“Interestingly what we’ve observed during the COVID pandemic is, across schools in the United States, the prevalence of drug use has gone down,” she said, “which likely very much reflects the fact that kids don’t have the opportunity to interact with others, and drug taking at that stage is a peer pressure behavior.”

The official also briefly addressed the fact that she feels criminalizing people over drugs in the first place is the wrong policy approach—a point she’s made repeatedly in interviews and blog posts.

She said that “criminalization has created a system for that allows a structural racism to be implemented, you can control people, and that’s a horrible policy. This criminalization actually opens up our eyes that well, yes, we need to change that.”

However, she said that “liberalizing and making the drugs widely available, with no counter messaging,” is not the alternative she would recommend.

While the SAM-hosted event did not touch specifically on psychedelics policy, Volkow has also recently discussed that issues, especially as data has shown an increase in use of the substances among adults.

She said people are going to keep using substances such as psilocybin—especially as the reform movement expands and there’s increased attention being drawn to the potential therapeutic benefits—and so researchers and regulators will need to keep up.

Volkow also mentioned that NIDA is “pleased” the Drug Enforcement Administration recently announced plans to significantly increase the quota of certain psychedelic drugs to be produced for use in research.

USDA Teams Up With Cornell University For Hemp Education Webinar Series

Photo courtesy of Philip Steffan.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment